StoxGlenmark Pharmaceuticals vs Abbott India: share price & financials comparison
NSE: GLENMARK vs ABBOTINDIA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glenmark Pharmaceuticals vs Abbott India at a glance
Glenmark Pharmaceuticals (GLENMARK) has a market capitalisation of ₹74,506 Cr, against ₹56,185 Cr for Abbott India (ABBOTINDIA). Over the past year Glenmark Pharmaceuticals has returned +43.1%, compared with -9.9% for Abbott India. On valuation, Abbott India trades at a lower P/E of 34.8 versus 84.1. Glenmark Pharmaceuticals comes out ahead on momentum and technicals. Abbott India comes out ahead on valuation, profitability and growth. Across the scored metrics below, Glenmark Pharmaceuticals leads on 6 and Abbott India on 6. On StoxGud's 10-point checklist, Glenmark Pharmaceuticals scores 5/10 and Abbott India scores 5/10.
| Metric | Glenmark Pharmaceuticals | Abbott India |
|---|---|---|
| Size | ||
| Market cap | ₹74,506 Cr | ₹56,185 Cr |
| Revenue (latest FY) | ₹16,983 Cr | — |
| Net profit (latest FY) | ₹0 Cr | — |
| Valuation | ||
| P/E | 84.1 | 34.8 |
| P/B | 6.64 | — |
| Dividend yield | 0.19% | — |
| Profitability | ||
| Return on equity | 7.9% | — |
| Net profit margin | 5.6% | 23.1% |
| Operating margin | 20.3% | 28.1% |
| Growth | ||
| Revenue growth (YoY) | -31.3% | +4.3% |
| Net profit growth (YoY) | -100.0% | +17.1% |
| Revenue CAGR (multi-year) | +9.2% | — |
| Financial health | ||
| Debt to equity | 0.08 | — |
| Momentum | ||
| 1-month return | +16.5% | +2.9% |
| 1-year return | +43.1% | -9.9% |
| 3-year CAGR | +53.9% | +4.5% |
| 5-year CAGR | +37.6% | +5.8% |
| 10-year CAGR | +11.7% | +19.3% |
| Distance from 52W high | -1.4% | -12.5% |
| Technicals | ||
| RSI (14) | 85 | 62 |
| Price vs 200-day avg | +17.4% | -0.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glenmark Pharmaceuticals | Abbott India |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✗ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 5/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glenmark Pharmaceuticals or Abbott India?
Glenmark Pharmaceuticals has a market cap of ₹74,506 Cr and Abbott India has a market cap of ₹56,185 Cr as of 13 Nov 2026.
Which has a lower P/E, Glenmark Pharmaceuticals or Abbott India?
Abbott India has the lower P/E: Glenmark Pharmaceuticals trades at 84.1 and Abbott India at 34.8.
Which gave better returns in the last year, Glenmark Pharmaceuticals or Abbott India?
Glenmark Pharmaceuticals did better: Glenmark Pharmaceuticals returned +43.1% and Abbott India returned -9.9% over one year.
What is the difference between Glenmark Pharmaceuticals and Abbott India?
Both are NSE-listed companies in Healthcare. Glenmark Pharmaceuticals is about 1.3 times the size of Abbott India by market cap. Operating margin is 20.3% for Glenmark Pharmaceuticals and 28.1% for Abbott India.
Which is better, Glenmark Pharmaceuticals or Abbott India?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Glenmark Pharmaceuticals leads on 6 and Abbott India on 6. Glenmark Pharmaceuticals is ahead on momentum and technicals. Abbott India is ahead on valuation, profitability and growth. On StoxGud's rules-based checklist Glenmark Pharmaceuticals scores 5/10 and Abbott India scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.